SK Biopharma preps Korea’s debut 2020 IPO, eyes $780m

Pharma_drugs_adobe_575x375.jpg
By Jonathan Breen
21 May 2020

SK Biopharmaceuticals is set to reopen the South Korean IPO market with a W959.3bn ($779.9m) listing, according to a source close to the deal.

The company, a subsidiary of Korean conglomerate SK Group, has hired Citi, Morgan Stanley and NH Investment & Securities as lead managers to run its listing.

It is offering 19.5m shares, equal to 25% of its outstanding share capital. The float is a mix of 13.3m new and ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.